NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
Clinical Trials
7 trialsNCT02393859 2024-05-29
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Completed
NCT04943952 2021-08-03
JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase
Jazz Pharmaceuticals
Approved for marketing
NCT01643408 2021-06-23
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
Jazz Pharmaceuticals
Phase 2 Completed
NCT02150928 2015-05-13
An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
Jazz Pharmaceuticals
Phase 2 Withdrawn
NCT00784017 2013-02-27
Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic Leukaemia
medac GmbH
Phase 3 Completed
NCT00983138 2011-03-01
Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)
medac GmbH
Phase 2 Completed